Abstract: The invention relates to a method for real-time tracking of the placement of a camera with respect to a 3D model comprising a keyframe base comprising a first thread of execution making it possible to estimate the current placement of the camera from a selected keyframe, characterized in that the method further comprises a step of analyzing the quality of the estimation of the placement of the camera from the image stored in a buffer memory, and a step of analyzing the sharpness of the image stored in the buffer memory from data representative of the movement of the camera, and if the quality of the estimation of the placement of the camera from the stored image and the sharpness of the stored image conform to predetermined criteria, a step of adding the image stored in the buffer memory to the keyframe base as a new keyframe.

Abstract: A composition comprising at least a mixture of molecules extracted from Chrysanthellum indicum, Cynara scolymus and Lycium barbarum. This composition is in particular useful as a nutritional product or health product to prevent and/or combat fat and/or carbohydrate metabolism disorders in Humans or animals.

Abstract: A method for fluorinating a filter for a pipette tip, the filter being made of a solid porous structure made of polyolefin. The method comprises the following steps: (a) placing the filter in an enclosure, (b) creating a vacuum in the enclosure, and (c) bringing the filter into contact with a fluorination agent injected into the enclosure in a gaseous state, the fluorination agent being made up of difluorine F2, the difluorine F2 being injected into the enclosure at a partial pressure between 100 Pa and 10000 Pa and step (c) being done at a temperature between 0° C. and 100° C. A pipette tip comprising a filter modified by the fluorination method, a method for producing such a tip, as well as a withdrawing pipette equipped with such a tip.

Abstract: A composition of yeast polysaccharides including ?(1,6)-glucans, preferably also mannans and ?-glucans. The yeast polysaccharides are extracted from yeast cell wall fragments. Typically, the ?-glucans are ?(1,6)-glucans. Also, a method for obtaining such a composition, including at least one step of fractionating a composition of yeast cell walls and extracting an insoluble fraction, and at least one step of extracting a soluble fraction from the insoluble fraction obtained in step a). Further, a composition with a human or veterinary therapeutic objective, for the treatment of gastrointestinal pathologies associated with pathogenic microorganisms, as well as to its non-therapeutic use for improving intestinal comfort.

Abstract: The invention relates to a composition comprising at least one specific mixture of molecules for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel diseases in humans or animals.

Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.

Abstract: The invention relates to a fluorination process consisting in bringing an inorganic compound M into contact with an atmosphere comprising difluorine gas, the inorganic compound M being a garnet based on the elements Li, La, Zr, A and O and for which the relative composition of the Li, La, Zr and A cations corresponds to the formula (I): LixLa3ZrzAw.

Abstract: The present invention concerns a process for isolating an archaeon of the order of commensal clade Methanomassiliicoccales, the use of a culture and/or isolation medium comprising a sterile extract of a bacterial culture of a bacterium of genus Eggerthella, for the isolation and/or culture of an archaeon of the order of commensal clade Methanomassiliicoccales, and a pure, isolated archaeon Methanomethylophilus alvus Mx-05. It also concerns a culture method of an archaeon of the order of commensal clade Methanomassiliicoccales.

Abstract: A mobile 3D printing device, system and method based on the addition of material intended to be attached to a lifting device with a single lifting cable or chain, including a printing head adapted to receive material and depositing it; fixing means adapted to link the printing head to the lifting device, and stabilization means adapted to stabilize the position of the printing head by a gyroscopic effect. The printing device enables the control of the printing of a structure to be printed, in particular the position of the printing head, to reduce the labor costs and the time to install such a device on a standard crane provided with a hook.

Abstract: The present invention relates to a method for preparing phosphorylated keto polyols by biocatalysis and uses thereof.

Abstract: A method of manufacturing nanoparticles of a photoluminescent material, including the successive steps of: a) forming nanometer-range particles of said photoluminescent material; b) forming a dispersion containing the particles in a non-aqueous solvent, the dispersion further containing at least one surface agent; c) placing the dispersion in an autoclave at a pressure in the range from 2 MPa to 100 MPa; and d) recovering the particles.

Abstract: The invention relates to an active pharmaceutical ingredient consisting exclusively of the combination of (1S,3R,4R,5R)-3-{[(2E)-3-(3,4-)dihydroxyphenyl)-2-propenoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid and of methyl (2S,3E,4S)-4-{2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl}-3-ethylidene-2-(?-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-5-carboxylate for use as a drug or veterinary product, particularly in the prevention and/or treatment of pathological disorders of carbohydrate and/or lipid metabolism.

Abstract: Gastro-intestinal release capsule intended for oral use in a method for desensitizing and/or inducing tolerance in a peanut-allergic subject or, alternatively, for diagnosing a peanut allergy in a subject. The capsule has a shell and a core, the core has a composition of peanut including peanut, at least one oil, at least one first pulverulent excipient and, optionally, at least one second prebiotic excipient. The capsule is provided and ingested in an unopened form.

Abstract: A composition comprising at least a mixture of molecules extracted from Chrysanthellum indicum, Cynara scolymus and Lycium barbarum. This composition is in particular useful as a nutritional product or health product to prevent and/or combat fat and/or carbohydrate metabolism disorders in Humans or animals.

Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.

Abstract: A composition comprising at least: a single extract obtained from a mixture of at least two plants selected from Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, Piper and Olea europaea. This composition is particularly useful as a nutritional product or health product for preventing and/or combating carbohydrate and/or fat metabolism disorders in humans and animals.

Abstract: A method for producing a photo-luminescent material, including the following steps: (1) producing, according to a sol-gel method, a sol and then a gel of first precursors of a first substance from the sol; (2) crushing the gel; (3) optionally, annealing the gel in order to form first particles of the first substance of which the average size is between 1 pm and 20 um; (4) producing a colloidal dispersion of second particles of a second substance, different from the first substance or identical to the first substance, of which the average size is between 5 nm and 400 nm; (5) mixing the colloidal dispersion with the sol in step (1) before forming the gel or with the first particles after step (3); and (6) annealing the mixture obtained in step (5), resulting in an increase in the compactness of the mixture, the average size of the second particles after annealing being between 100 nm and 900 nm.

Abstract: The invention relates to an implant material for filling bone defects, for bone regeneration, and for bone tissue engineering, to an implant comprising said material, and to methods for manufacturing such an implant. The hybrid implant material according to the invention comprises: a biodegradable polymer P soluble in at least one solvent S1 and insoluble in at least one solvent S, different from the solvent S1; and a bioactive glass made of SiO2 and CaO and optionally containing P2O5 and/or optionally doped with strontium, characterized in that said implant includes a layering of a porous part having more than 90% by number of pores whose largest dimension is greater than or equal to 100 ?m, and a dense part (2, 20, 200, 2000, 20000) having more than 80% by number of pores whose largest dimension is less than 50 ?m. The invention is useful in the field of bone regeneration, particularly in the field of bone tissue engineering.

Abstract: The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO—(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X? represents OH or X and X? taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6)-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO—(C1-C6)-alkyl, CF3 or COCF3, and R is as described in claim 1.

Abstract: A composition including at least one XAP peptide, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase. Also, the use of a hydrolysate of at least one protein, the protein including or constituted by at least 0.05% to <5% or of at least 5% of XAP units, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase.